Identification and validation of LY6H and GRM3 as candidate biomarkers for Glioma-related epilepsy.

Gliomas are the most common primary tumors of the central nervous system, with epilepsy serving as a frequent clinical manifestation. Glioma-related epilepsy (GRE) significantly affects patients' quality of life and prognosis. In this study, we integrated bioinformatics and multiple machine learning methods to perform a proteomic analysis of brain tumor samples from patients with GRE and from those with gliomas none epilepsy (GNE). Our findings identified LY6H and GRM3 as potential signature proteins of GRE. Further investigation showed that LY6H and GRM3 expression levels were markedly reduced in GRE samples, with favorable diagnostic performance according to ROC curve analyses. Finally, we conducted an independent external validation using the Bluk-RNA dataset GSE199759, and the results corroborated our prior analyses. This work not only provides new biomarkers for the early detection of GRE but also offers valuable insights into its molecular mechanisms and potential therapeutic strategies.